Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Hypertension 2Prostatic Neoplasms 1Pancreatic Neoplasms 1Melanoma 1Lymphoma, Follicular 1Cardiovascular Diseases 1Cardiotoxicity 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21Specimen Handling 20CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Melanoma × Angiotensin-Converting Enzyme Inhibitors × Clear all
NCT04334824 2024-09-19

Hydrochlorothiazide and Risk of Skin Cancer

Canadian Network for Observational Drug Effect Studies, CNODES

Completed
2,953,748 enrolled
Dermatologic

Hypertension, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡